Affiliation:
1. Pavlov First Saint Petersburg State Medical University
Abstract
Introduction. Rhinosinusitis, along with adenoiditis, holds leading positions in terms of incidence among adults and children. About 10 million cases of rhinosinusitis per year are reported in Russia.Aim. To study the effectiveness and safety of secretolytic drugs in the treatment of acute rhinosinusitis in different groups of patients, features of the course of rhinosinusitis in patients with concomitant disorders of the immune system.Materials and methods. A total of 98 medical records of children with acute sinusitis that was diagnosed by an otolaryngologist during the initial examination based on complaints, past medical history data and paranasal sinuses x-rays were selected for analysis. Of these, 60 children aged 3 to 15 years (23 girls and 37 boys) were included in Group 1. 38 immunocompromised children aged 3 to 12 years (18 girls and 20 boys) were included in Group 2.Results. In the group of patients without oncohematological diseases (Group 1), the average duration of bacterial sinusitis was from 6 to 12 days, if the standard treatment regimen was ussed; if therapy included Sinupret complex-action herbal medicine, children were ill for an average of 6.46 days, and the average duration of the disease in patients who did not receive the herbal medicine was 3 days longer, totalling to 9.54 days. Patients with various immunocompromising diseases, who received specific immunosuppressive therapy, on average were ill significantly longer – from 8 to 16 days on systemic antibacterial therapy. Moreover, the average duration of sinusitis in patients, who additionally used Sinupret was 7.5 days, which was almost 5 days less (12.4) than in patients, who received treatment without Sinupret herbal medicine. The article also presented the results of treatment of patients receiving several immunosuppressive drugs, who had a graft-versus-host reaction, cytopenia and other unfavorable factors.Conclusion. The inclusion of the herbal medicine with complex action in the treatment regimen significantly improves the positive effect of therapy, reduces the duration and intensity of clinical presentations, even if a patient has immunological diseases and immunocompromising conditions.
Reference21 articles.
1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/Rhin20.600.
2. Kryukov AI, Turovskii AB, Kolbanova IG, Musaev KM, Karasov AB. Guidelines for the acute respiratory viral infection treatment. RMJ. 2019;8(I):46–50. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Osnovnye_principy_lecheniya_ostroy_respiratornoy_virusnoy_infekcii/?utm_source=google.com&utm_medium=organic&utm_campaign=google.com&utm_referrer=google.com.
3. Starostina SV, Sivokhin DA. Topical therapy in the treatment of patients with acute rhinosinusitis in adults. Consilium Medicum. 2021;23(3):210–215. (In Russ.) Available at: https://omnidoctor.ru/upload/iblock/cb6/cb697ffa753ae0607052975a1a954309.pdf.
4. Popadyuk VI, Bitsaeva AV, Fomina AV. Management and quality of outpatient and inpatient care to patients with diseases of the nasal cavity and paranasal sinuses (results of a survey). Meditsinskiy Sovet. 2014;(15):10–12. (In Russ.) https://doi.org/10.21518/2079-701X-2014-15-10-12
5. Karpischenko SA, Tikhomirova EK. Rhinitis in children of the first years of life. Pediatrics. Consilium Medicum. 2021;(3):224–230. Available at: https://omnidoctor.ru/upload/iblock/f7d/f7d2978e16a6492e0e7787eca9c44949.pdf.